Lipidor AB advances in Phase III

This evening Lipidor AB announced that the first patient has now been enrolled in the Phase III clinical study with AKP02G2. With this announcement yet another milestone is being met on time showing that CEO Ola Holmlund and his team are delivering as scheduled. We look forward to getting to know when more centers becomes active, and we still anticipate, that the end result will be delivered in Q1 2025.